1,589 results match your criteria: "Kliniken Essen-Mitte; University of Duisburg-Essen[Affiliation]"

Article Synopsis
  • The text discusses a necessary correction to a previously published article identified by the DOI 10.1055/a-2238-3153.
  • It highlights the importance of accuracy in scientific publications and the impact of corrections on the integrity of research.
  • This rectification ensures that readers and researchers rely on correct information when referencing the work.
View Article and Find Full Text PDF
Article Synopsis
  • The iNAP® Sleep Therapy System effectively reduces the severity of obstructive sleep apnea by applying negative oral pressure through an intra-oral device.
  • In a study involving 130 patients, over half (52%) showed significant improvement with more than 50% reduction in apnea-hypopnea index (AHI) after using the device.
  • The system was well-tolerated with low adverse events, and improvements in oxygen saturation and AHI were maintained even 28 days after treatment.
View Article and Find Full Text PDF
Article Synopsis
  • Ovarian cancer, especially in its platinum-resistant form (PROC), presents significant challenges due to limited treatment options and poor prognosis for patients.
  • This study aimed to find markers for monitoring treatment response in 123 PROC patients participating in the GANNET53 clinical trial assessing Ganetespib combined with standard chemotherapy.
  • Results showed that the presence of the ERCC1 gene was linked to a higher risk of disease progression, while the CDH1 and ESR1 genes appeared to have a protective effect, suggesting the potential of using liquid biopsy samples for better disease management.
View Article and Find Full Text PDF

Background: The GENEVIEVE study, comparing neoadjuvant cabazitaxel versus paclitaxel in triple-negative breast cancer (TNBC) and luminal B/human epidermal growth factor receptor 2 (HER2)-negative breast cancer (BC), previously reported significant differences in pathological complete response (pCR) rates. Effects on long-term outcome are unknown.

Patients And Methods: GENEVIEVE randomized patients with cT2-3, any cN or cT1, cN+/pN+, centrally confirmed TNBC or luminal B/HER2-negative BC (latter defined as estrogen/progesterone receptor-positive and >14% Ki-67-stained cells) to receive either cabazitaxel 25 mg/m q3w for four cycles or paclitaxel 80 mg/m weekly for 12 weeks.

View Article and Find Full Text PDF

Importance: Data on oncological outcomes after omission of axillary lymph node dissection (ALND) in patients with breast cancer that downstages from node positive to negative with neoadjuvant chemotherapy are sparse. Additionally, the best axillary surgical staging technique in this scenario is unknown.

Objective: To investigate oncological outcomes after sentinel lymph node biopsy (SLNB) with dual-tracer mapping or targeted axillary dissection (TAD), which combines SLNB with localization and retrieval of the clipped lymph node.

View Article and Find Full Text PDF

Long-term outcome of retroperitoneoscopic partial versus total adrenalectomy in patients with Cushing's syndrome.

World J Surg

January 2024

Klinik für Chirurgie und Zentrum für Minimal Invasive Chirurgie, Kliniken Essen-Mitte, Essen, Germany.

Background: We analyze the long-term outcome of surgery for Cushing's syndrome (CS) and the influence of the extent of surgical resection on the duration of postoperative cortisone substitution.

Methods: One-hundred forty-one patients (129 female, 12 males; mean age: 45.7 ± 12.

View Article and Find Full Text PDF

Secondary cytoreductive surgery and oncologic outcomes in the era of targeted maintenance therapy for recurrent, platinum-sensitive ovarian cancer.

Gynecol Oncol

July 2024

Gynecology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA; Department of OB/GYN, Weill Cornell Medical College, New York, NY, USA. Electronic address:

Objectives: To compare oncologic outcomes of secondary cytoreductive surgery (SCS) before and after FDA approval of Poly(ADP-ribose) polymerase inhibitor (PARPi) and bevacizumab maintenance therapies for platinum-sensitive recurrent ovarian cancer (PS-ROC).

Methods: Patients who underwent SCS for first recurrence of PS-ROC from 1/1/2013-1/1/2020 were identified. Exclusion criteria included prior chemotherapy for recurrence, bowel obstruction procedures, and palliative surgery.

View Article and Find Full Text PDF

Role of fertility-sparing surgery and further prognostic factors in borderline tumors of the ovary.

Int J Gynecol Cancer

June 2024

Department of Gynecology and Gynecologic Oncology, Ev. Kliniken Essen-Mitte, Essen, Germany.

Objective: Borderline tumors of the ovary are a rare group of ovarian neoplasms with distinctive histological features. Considering their favorable prognosis and occurrence at a younger age, fertility-sparing surgery may be considered. Several risk factors have been identified as contributing to a higher recurrence rate, while the impact of pathohistological features varies in the literature.

View Article and Find Full Text PDF

[Not Available].

Z Gastroenterol

April 2024

Gastroenterologische Praxis am Kreiskrankenhaus Osterholz, Osterholz-Scharmbeck.

View Article and Find Full Text PDF

[New S2k guideline "Surgical techniques for gender incongruence"].

Urologie

May 2024

Klinik für Urologie, Kinderurologie und Uroonkologie, Universitätsklinikum Essen, Essen, Deutschland.

Background: Various techniques for the surgical treatment of gender incongruence (GI) have been available for years. The spectrum is broad and covers various specialties. In recent years, there has been an increase in the number of clinics offering body-modifying procedures.

View Article and Find Full Text PDF

[Differences in sexual development-S2k guideline update].

Urologie

May 2024

Triagon Dortmund, Hormonzentrum für Kinder und Jugendliche, Dortmund, Deutschland.

Background: Human beings with a difference in sexual development (DSD) often underwent gender reassignment surgery during early childhood. However, the medical decision was often not congruent with the gender identity that affected persons developed later on.

Objectives: To represent the interests of affected persons, an interdisciplinary guideline in cooperation with support groups was written.

View Article and Find Full Text PDF
Article Synopsis
  • The study compares the effectiveness of atezolizumab plus cabozantinib versus docetaxel in patients with advanced non-small cell lung cancer (NSCLC) who did not respond to prior immunotherapy and chemotherapy.
  • Results showed similar overall survival rates: 10.7 months for the combination treatment and 10.5 months for docetaxel, with both showing comparable median progression-free survival.
  • Adverse events were reported in both treatment groups; however, a higher percentage of serious adverse events occurred in those receiving atezolizumab plus cabozantinib compared to docetaxel.
View Article and Find Full Text PDF

Platinum and taxane chemotherapy is associated with the risk of hypersensitivity reactions (HSRs), which may require switching to less effective treatments. Desensitization to platinum and taxane HSRs can be used to complete chemotherapy according to the standard regimen. Therefore, we aimed to investigate the current management of HSRs to platinum and/or taxane chemotherapy in patients with gynecologic cancers.

View Article and Find Full Text PDF

Reconstruction of Orbital Exenteration Defects with Cross-median Forehead Flaps.

Facial Plast Surg

December 2024

Department of Oral and Maxillofacial Surgery, University of Duisburg-Essen, Kliniken-Essen-Mitte, Essen, Germany.

The aim of this study was to examine the role of forehead flaps in the reconstruction of orbital defects after exenteration. Patients undergoing orbital exenteration and reconstruction using median forehead flaps from January 2002 to August 2019 were enrolled in this retrospective study. All the patients were evaluated for wound complications, functional results, and tumor relapse.

View Article and Find Full Text PDF

Paclitaxel therapeutic drug monitoring - International association of therapeutic drug monitoring and clinical toxicology recommendations.

Eur J Cancer

May 2024

Cancer Therapeutics Program, UPMC Hillman Cancer Center, Pittsburgh, PA, USA; Department of Pharmaceutical Sciences, School of Pharmacy, University of Pittsburgh, Pittsburgh, PA, USA; Division of Hematology-Oncology, Department of Medicine, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA. Electronic address:

Paclitaxel, one of the most frequently used anticancer drugs, is dosed by body surface area, which leads to substantial inter-individual variability in systemic drug exposure. We evaluated clinical evidence regarding the scientific rationale and clinical benefit of individualized paclitaxel dosing based on measured systemic concentrations, known as therapeutic drug monitoring (TDM). In retrospective studies, higher systemic exposure is associated with greater toxicity and efficacy of paclitaxel treatment across several disease types and dosing regimens.

View Article and Find Full Text PDF

Objectives: To investigate, whether inflammatory rheumatic diseases (IRD) inpatients are at higher risk to develop a severe course of SARS-CoV-2 infections compared to the general population, data from the German COVID-19 registry for IRD patients and data from the Lean European Survey on SARS-CoV-2 (LEOSS) infected patients covering inpatients from the general population with SARS-CoV-2 infections were compared.

Methods: 4310 (LEOSS registry) and 1139 cases (IRD registry) were collected in general. Data were matched for age and gender.

View Article and Find Full Text PDF

Background: In hospital cleaning, there is currently no standard for uniform monitoring of surface cleaning, either in Germany or internationally. One possibility for monitoring is the use of so-called objective methods for checking cleaning performance (e.g.

View Article and Find Full Text PDF

Changes over time in the course of advanced pancreatic cancer treatment with systemic chemotherapy: a pooled analysis of five clinical trials from two decades of the German AIO study group.

ESMO Open

April 2024

Department of Medicine III, LMU Munich, Munich; Comprehensive Cancer Center, LMU Munich, Munich; Department of Hematology and Oncology, München Klinik Neuperlach, Munich, Germany. Electronic address:

Background: Over the past two decades, our group has conducted five multicenter trials focusing on first-line systemic therapy for patients with advanced pancreatic cancer. The current pooled analysis was designed to evaluate prognosis over time and the impact of clinical characteristics on survival.

Patients And Methods: Individual patient data were derived from five prospective, controlled, multicenter trials conducted by the 'Arbeitsgemeinschaft Internistische Onkologie' (AIO): 'Gem/Cis', 'Ro96', 'RC57', 'ACCEPT' and 'RASH', which recruited patients between December 1997 and January 2017.

View Article and Find Full Text PDF

Background: Nineteen genomic regions have been associated with high-grade serous ovarian cancer (HGSOC). We used data from the Ovarian Cancer Association Consortium (OCAC), Consortium of Investigators of Modifiers of (CIMBA), UK Biobank (UKBB), and FinnGen to identify novel HGSOC susceptibility loci and develop polygenic scores (PGS).

Methods: We analyzed >22 million variants for 398,238 women.

View Article and Find Full Text PDF

Background: Before the era of immunotherapies and antibody-drug conjugates, there were limited chemotherapeutic options for patients with recurrent and metastatic cervical cancer. Combination therapies with cisplatin have shown some superiority over monotherapy. This study examined platinum-free treatment regimens, comparing a combination of topotecan and paclitaxel (TP) with topotecan and cisplatin (TC) in patients with recurrent or metastatic cervical cancer, with or without prior platinum-based treatment.

View Article and Find Full Text PDF
Article Synopsis
  • - The study aimed to validate the SeqOne assay for detecting homologous recombination deficiency (HRD) using tumor samples from the PAOLA-1 trial, comparing it to the Myriad MyChoice HRD test.
  • - Results showed a high concordance rate of 95% between the two tests in determining HRD status, with both assays suggesting significant benefits of olaparib plus bevacizumab treatment for patients with HRD-positive tumors.
  • - The findings indicate that the SeqOne assay is a clinically validated method for detecting HRD, which can help tailor treatment strategies for advanced ovarian cancer patients.
View Article and Find Full Text PDF

MR Imaging Characteristics of Solitary Fibrous Tumors of the Orbit : Case Series of 18 Patients.

Clin Neuroradiol

September 2024

Institute of Diagnostic and Interventional Radiology and Neuroradiology, University Hospital Essen, Hufelandstraße 55, 45147, Essen, Germany.

Purpose: Solitary fibrous tumor (SFT) of the orbit is a rare tumor that was first described in 1994. We aimed to investigate its imaging characteristics that may facilitate the differential diagnosis between SFT and other types of orbital tumors.

Material And Methods: Magnetic resonance imaging (MRI) data of patients with immunohistochemically confirmed orbital SFT from 2002 to 2022 at a tertiary care center were retrospectively analyzed.

View Article and Find Full Text PDF
Article Synopsis
  • Survival rates for ovarian cancer are influenced by the success of primary surgery in removing tumors.
  • Researchers conducted genome-wide studies on 7,705 ovarian cancer patients to find genetic variants linked to resection status, particularly focusing on high-grade serous carcinoma (HGSOC).
  • The study highlighted significant associations with the rs72845444 variant and the genes MGMT (involved in DNA repair) and PPP2R5C (a tumor suppressor), correlating with disease outcomes and patient survival.*
View Article and Find Full Text PDF